Infection · lung transplant recipients
Polyclonal T‐cell antibody induction showed no clear difference in infection compared with interleukin‐2 receptor antagonist induction (moderate certainty).
1 finding from 1 review
Bronchiolitis obliterans syndrome · lung transplant recipients
Polyclonal T‐cell antibody induction showed no clear difference in bronchiolitis obliterans syndrome compared with interleukin‐2 receptor antagonist induction (moderate certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality · HIV‐positive adults
The intervention showed no clear difference in all‐cause mortality (high certainty).
1 finding from 1 review
Intervention not reported
CD4 cell count · HIV‐positive adults
1 finding from 1 review
Intervention not reported
HIV RNA levels less than 50 cells/mL · HIV‐positive adults
The intervention showed no clear difference in HIV RNA levels less than 50 cells/mL (high certainty).
1 finding from 1 review
Intervention not reported
HIV RNA levels less than 500 cells/mL · HIV‐positive adults
The intervention showed no clear difference in HIV RNA levels less than 500 cells/mL (high certainty).
1 finding from 1 review
Intervention not reported
Opportunistic infections · HIV‐positive adults
The intervention showed no clear difference in opportunistic infections (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events (grade 3 or 4) · HIV‐positive adults
The intervention probably leads to higher adverse events (grade 3 or 4) (moderate certainty).
1 finding from 1 review
Intervention not reported
Relapses/death (instead of disease‐free survival）[2] · People with AML in first complete remission
The intervention showed no clear difference in relapses/death (instead of disease‐free survival）[2] (low certainty).
1 finding from 1 review
Intervention not reported
Mortality (instead of overall survival)[2] · People with AML in first complete remission
The intervention showed no clear difference in mortality (instead of overall survival)[2] (moderate certainty).
1 finding from 1 review
Intervention not reported
Death/progress (instead of event‐free survival)[2] · People with AML in first complete remission
The intervention showed no clear difference in death/progress (instead of event‐free survival)[2] (low certainty).
1 finding from 1 review
Intervention not reported
Treatment‐related mortality · People with AML in first complete remission
1 finding from 1 review
Intervention not reported
Adverse events: hypersensitivity · People with AML in first complete remission
It is very uncertain whether the intervention changes adverse events: hypersensitivity (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events: fatigue · People with AML in first complete remission
It is very uncertain whether the intervention changes adverse events: fatigue (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events: rigor/chills · People with AML in first complete remission
It is very uncertain whether the intervention changes adverse events: rigor/chills (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events: arthralgia/myalgia · People with AML in first complete remission
It is very uncertain whether the intervention changes adverse events: arthralgia/myalgia (very low certainty).
1 finding from 1 review
Intervention not reported
Quality of life · People with AML in first complete remission
1 finding from 1 review